Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
    Home » News » Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma
News

Shivalik Rasayan Ltd inks marketing agreement with China Chinopharma

The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.

  • By IPP Bureau | August 03, 2022

Shivalik Rasayan Ltd has entered into a long term marketing agreement with China Chinopharma Limited (CSC) to supply DMF grade BUSALFAN, API.

The CSC shall hold Market Authorisation (MA) to sell SRL's BUSALFAN, API exclusively in China territory.

The CSC is a leader and pioneer who specialises in dealing with Pharmaceutical products having more than 20 years of experience.

Upcoming E-conference

Other Related stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
Sigachi Industries signs MoU with Respilon Group
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
View More

Interviews

India rema
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex comm
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Our focus
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
View More

Appointments

Abbott India elevates Maithilee Pathare Mistry as CFO
Abbott India elevates Maithilee Pathare Mistry as CFO
Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy
Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy
Shaik Barak Tulla joins Sun Pharma as Sr. VP
Shaik Barak Tulla joins Sun Pharma as Sr. VP
View More

Startup

Hyderabad based CSIR institutes playing pivotal role in drug discovery and genetic diagnostics: Dr. Jitendra Singh
Hyderabad based CSIR institutes playing pivotal role in drug discovery and genetic diagnostics: Dr. Jitendra Singh
Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital
Mila Beaute raises $2.16 million in pre-series A round led by Rukam Capital
Merck Life Science India signs MoU with DPIIT
Merck Life Science India signs MoU with DPIIT
View More

Digitization

Wanbury to implement the SAP S/4 HANA private cloud platform
Wanbury to implement the SAP S/4 HANA private cloud platform
Rockwell Automation empowers NKP Pharma achieve regulatory compliance
Rockwell Automation empowers NKP Pharma achieve regulatory compliance
Honeywell launches AI-assisted automation platform for life sciences manufacturing industry
Honeywell launches AI-assisted automation platform for life sciences manufacturing industry
View More

Latest Stories

Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr

Sigachi Industries signs MoU with Respilon Group

USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility

Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Opinion
Injection filter needle market to reach $1.73 billion in 2025
Injection filter needle market to reach $1.73 billion in 2025
Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals
Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging